Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?


Drug Profile


Alternative Names: Acadra; AICA riboside; ARA 100; Arasine; ATH 001; GP 1 110; Protara; SCH 900395

Latest Information Update: 04 Nov 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator AdvanCell; SICOR
  • Developer Advancell; Groupe Francophone des Myelodysplasies; Merck & Co; SICOR
  • Class Amides; Antineoplastics; Antiplatelets; Imidazoles; Ribonucleosides; Small molecules
  • Mechanism of Action Apoptosis stimulants; Platelet aggregation inhibitors; Purinergic P1 receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Chronic lymphocytic leukaemia
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • No development reported Chronic lymphocytic leukaemia; Mantle-cell lymphoma; Multiple myeloma; Myelodysplastic syndromes
  • Discontinued Asthma; Diabetes mellitus; Ischaemic heart disorders; Thrombosis

Most Recent Events

  • 07 Nov 2016 AdvanCell terminates a phase I/II trial for Myelodysplastic syndromes (Treatment-resistant, Recurrent) in France prior to November 2016 (NCT01813838)
  • 16 Sep 2015 No recent reports on development identified - Phase-I/II for Chronic lymphocytic leukaemia (Second-line therapy or greater) in Belgium, France and Spain (IV)
  • 13 Nov 2011 Preclinical pharmacodynamics data presented at the 23rd AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics (AACR-NCI-EORTC-2011)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top